Predicting the Risk of Symptomatic Intracerebral Hemorrhage in Ischemic Stroke Treated With Intravenous Alteplase

Mazya et al. (Fri,) studied this question.

www.synapsesocial.com/papers/69db1dcc498b35d3e6a3c7f0 — DOI: https://doi.org/10.1161/strokeaha.111.644815

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy at Stroke Onset· 2010 · 121 citations
2. Thrombolysis with alteplase 3–4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study· 2008 · 569 citations
3. Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator· 2009 · 825 citations
4. Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials· 2008 · 438 citations
5. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke· 2008 · 6,607 citations